1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 10,800 | 11,200 | 16:21 | |
| 10,800 | 11,200 | 16:18 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13:36 | MiNK Therapeutics Reports Q3 2025 Results and Accelerates iNKT Platform Toward Pivotal Development Across Oncology, Pulmonary Disease, and Transplantation | 77 | GlobeNewswire (Europe) | New clinical data show durable remissions and long-tail survivors including >2-year complete remissions in chemotherapy- and checkpoint-refractory cancersGVHD trial launching through non-dilutive... ► Artikel lesen | |
| MINK THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13:36 | MiNK Therapeutics GAAP EPS of -$0.65 beats by $0.20 | 1 | Seeking Alpha | ||
| 07.11. | MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1-Refractory Solid Tumors at SITC 2025 | 152 | GlobeNewswire (Europe) | Durable survival and deep, lasting remissions in checkpoint-refractory, heavily pretreated cancers with median OS of ~23 months with agenT-797 plus anti-PD-1Evidence of immune activation and tumor-immune... ► Artikel lesen | |
| 05.11. | MiNK Therapeutics to Report Third Quarter 2025 Financial Results and Highlight Clinical and Corporate Milestones Advancing iNKT Platform Toward Pivotal Development | 3 | GlobeNewswire (USA) | ||
| 30.10. | MiNK Therapeutics to Present Late-Breaking Data on AgenT-797 in Solid Tumors at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting | 3 | GlobeNewswire (USA) | ||
| 29.09. | MiNK Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 29.09. | MiNK Therapeutics appoints trauma expert Dr. John Holcomb to board | 2 | Investing.com | ||
| 29.09. | MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors | 10 | GlobeNewswire (USA) | ||
| 25.09. | MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA | 2 | GlobeNewswire (USA) | ||
| 18.09. | MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development | 1 | GlobeNewswire (USA) | ||
| 15.08. | MiNK Therapeutics stock rating upgraded to Buy by H.C. Wainwright on financial results | 3 | Investing.com | ||
| 14.08. | MiNK Therapeutics GAAP EPS of -$1.06 misses by $0.51 | 4 | Seeking Alpha | ||
| 14.08. | MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results | 167 | GlobeNewswire (Europe) | Cash runway extended to deliver clinical program in GVHD and Ph2 results in 2L Gastric CancerDepartment of Defense STTR Grant to advance INKTs in GVHD announced; program advancingNew clinical grant... ► Artikel lesen | |
| 14.08. | MiNK Therapeutics, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | MiNK Therapeutics: H.C. Wainwright stuft Aktie nach Kursrallye auf "Neutral" herab | 17 | Investing.com Deutsch | ||
| 15.07. | MiNK Therapeutics stock rating downgraded to Neutral by H.C. Wainwright | 2 | Investing.com | ||
| 15.07. | Mink Therapeutics stock tumbles on $50 million stock offering | 5 | Investing.com | ||
| 15.07. | MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy | 1 | GlobeNewswire (USA) | ||
| 15.07. | Nach Kursrallye von über 460 %: MiNK Therapeutics kündigt Kapitalerhöhung über 50 Mio. US-Dollar an | 5 | Investing.com Deutsch | ||
| 14.07. | William Blair stuft MiNK-Therapeutics-Aktie nach 700-%-Rallye herab | 9 | Investing.com Deutsch |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BB BIOTECH | 44,800 | +0,45 % | BB Biotech im Aufwind - Zinswende treibt Biotech-Rally an | US-Zinssenkung belebt den Biotech-Sektor. BB Biotech glänzt mit starkem Quartal, vier Exits und klarer Outperformance gegenüber dem Nasdaq Biotech Index. Seit der ersten Zinssenkung der US-Notenbank... ► Artikel lesen | |
| VIKING THERAPEUTICS | 33,360 | -0,51 % | Novo Nordisk, Eli Lilly oder Viking Therapeutics: Wer gewinnt den Dreikampf? | Der Markt für Adipositas-Medikamente boomt - und die Konkurrenz zwischen den Schwergewichten Novo Nordisk und Eli Lilly prägt das Geschehen. Doch während sich die Giganten duellieren, könnte das viel... ► Artikel lesen | |
| NOVOCURE | 9,874 | +0,96 % | Novocure to Participate in 2025 Jefferies Global Healthcare Conference | Novocure (NASDAQ: NVCR) announced today that management will participate in the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025. Ashley Cordova, Chief Executive Officer... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,476 | -4,03 % | Oxford Nanopore Tech - Share Incentive Plan - Director/PDMR Shareholding | ||
| MEREO BIOPHARMA | 1,475 | -3,91 % | Mereo BioPharma Group plc - 8-K, Current Report | ||
| BIOLINERX | 2,730 | -0,91 % | XFRA YP2: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| ASSERTIO | 0,800 | -2,44 % | Assertio narrows 2025 guidance to $110M-$112M as Rolvedon pull-forward shapes cash flow outlook | ||
| APPLIED THERAPEUTICS | 0,235 | -2,70 % | Applied Therapeutics Tanks As FDA Path For Lead Rare-Disease Drug Turns Uncertain | ||
| ROIVANT SCIENCES | 17,380 | -1,70 % | Guggenheim raises Roivant Sciences stock price target to $25 on pipeline progress | ||
| AKERO THERAPEUTICS | 46,750 | +0,30 % | Laufende Fusionskontrollverfahren: Novo Nordisk A /S, Bagsvaerd /Dänemark; Erwerb sämtlicher Anteile an der und alleiniger Kontrolle über die Akero Therapeutics, Inc., South San Francisco /CA /USA | Datum der Anmeldung:05.11.2025Aktenzeichen:B3-105/25Unternehmen:Novo Nordisk A/S, Bagsvaerd/Dänemark; Erwerb sämtlicher Anteile an der und alleiniger Kontrolle über die Akero Therapeutics, Inc., South... ► Artikel lesen | |
| REVOLUTION MEDICINES | 54,50 | -1,80 % | Revolution Medicines, Inc.: Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress | Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026Company has... ► Artikel lesen | |
| ARVINAS | 10,070 | -0,40 % | Stephens raises Arvinas stock price target to $15 on program updates | ||
| JANUX THERAPEUTICS | 28,300 | +3,06 % | Janux Therapeutics GAAP EPS of -$0.39 beats by $0.23, revenue of $10M beats by $6.93M | ||
| WEREWOLF THERAPEUTICS | 0,895 | -3,02 % | Werewolf Therapeutics, Inc.: Werewolf Therapeutics Receives Fast Track Designation from the U.S. FDA for WTX-124, an Investigational Therapy for the Treatment of Cancer | Fast Track Designation underscores the promise of Werewolf's INDUKINE platform WATERTOWN, Mass., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq:... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 8,420 | 0,00 % | TransCode Therapeutics, Inc.: TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO | Safety primary endpoint achieved
Median treatment duration of 4 months with a range of 2 to 12 months and three patients remain on trial
RECIST data with... ► Artikel lesen |
Das Unternehmen MINK THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,600 (-5,50 %) liegt der Kurs bei 10,300 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MINK THERAPEUTICS INC finden Sie auf Wallstreet Online.